Abrax Company History
Abrax History
2020
Abrax Project initiated by Dr. Taku Kambayashi
Co-founder, Dr. Kambayashi’s intent to bring his decades of basic research to fruition
Mr. Jo Narita’s inauguration as the CEO
Bringing in vast experience in the global business for acceleration of commercialization
Abrax Japan established
A corporation established in Japan with Seed 1 funding
Seed 2 fundraise
¥190 million raised from a venture capital and private investors
Business partnership with Camargo
Establishment of a regulatory strategy team for new drug approval through business partnership
Business partnership with Tergus Biopharma
Initiation of new drug formulation with Tergus Biopharma through business partnership
Seed 3 fundraise
JPY 50 million raised from private investors
2021
Completion of ABX-919 formulation
A new formulation produced by Tergus Biopharma and code-named “ABX-919”
Publication in one of the most prominent journals in the world by Dr. Kambayashi
Dr. Kambayashi’s research published in the journal Science (Vol. 373, Issue 6554)
Seed 4 fundraise
JPY 250 million raised from the existing investors to support a pre-clinical and clinical studies
Reaching over JPY 1 billion in corporate valuation
Surpassing JPY 1 billion in corporate valuation upon completion of Seed 4 fundraise
Establishment of Australian subsidiary
Establishment of Abrax Australia Pty. Ltd. for execution of clinical trials in Australia
And our stories continue…